Holen Sie sich die Stockscreener-App
15.56
0.81%
0.15
Handel nachbörslich:
15.32
-0.24
-1.54%
Schlusskurs vom Vortag:
$15.41
Offen:
$15.42
24-Stunden-Volumen:
806.87K
Relative Volume:
1.42
Marktkapitalisierung:
$631.98M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-168.05M
KGV:
-3.0331
EPS:
-5.13
Netto-Cashflow:
$-146.15M
1W Leistung:
+7.21%
1M Leistung:
-2.30%
6M Leistung:
+11.84%
1J Leistung:
-73.82%
1-Tages-Spanne:
$15.03
$15.76
1-Wochen-Bereich:
$13.60
$15.76
52-Wochen-Spanne:
$9.12
$72.37
Keros Therapeutics Inc Stock (KROS) Company Profile
Firmenname
Keros Therapeutics Inc
Sektor
Branche
Telefon
617-314-6297
Adresse
1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA
Vergleichen Sie KROS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KROS
Keros Therapeutics Inc
|
15.56 | 469.48M | 0 | -168.05M | -146.15M | -5.13 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.43 | 109.29B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.90 | 62.13B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
584.65 | 61.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
813.45 | 51.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
313.96 | 34.68B | 4.56B | -176.77M | 225.30M | -1.7177 |
Keros Therapeutics Inc Stock (KROS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-20 | Eingeleitet | Wells Fargo | Overweight |
| 2025-06-10 | Herabstufung | BofA Securities | Buy → Neutral |
| 2025-01-21 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2025-01-17 | Herabstufung | Wedbush | Outperform → Neutral |
| 2024-12-16 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-12-16 | Bestätigt | Oppenheimer | Outperform |
| 2024-12-13 | Bestätigt | H.C. Wainwright | Buy |
| 2024-12-12 | Herabstufung | BTIG Research | Buy → Neutral |
| 2024-12-12 | Herabstufung | TD Cowen | Buy → Hold |
| 2024-12-12 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2024-11-05 | Eingeleitet | Jefferies | Buy |
| 2024-10-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-09-23 | Eingeleitet | Guggenheim | Buy |
| 2024-06-25 | Eingeleitet | Oppenheimer | Outperform |
| 2024-02-21 | Eingeleitet | William Blair | Outperform |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2023-07-31 | Eingeleitet | Wedbush | Outperform |
| 2023-07-26 | Eingeleitet | BofA Securities | Buy |
| 2023-02-14 | Eingeleitet | Cowen | Outperform |
| 2022-10-18 | Eingeleitet | Truist | Buy |
| 2022-07-26 | Eingeleitet | BTIG Research | Buy |
| 2020-12-08 | Bestätigt | H.C. Wainwright | Buy |
| 2020-05-04 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-05-04 | Eingeleitet | Jefferies | Buy |
| 2020-05-04 | Eingeleitet | Piper Sandler | Overweight |
| 2020-05-04 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Keros Therapeutics Inc Aktie (KROS) Neueste Nachrichten
Technical Reactions to KROS Trends in Macro Strategies - news.stocktradersdaily.com
Keros Therapeutics (KROS) Moves 9.8% Higher: Will This Strength Last? - Yahoo Finance
Can Keros Therapeutics Inc. recover in the next quarterMarket Risk Summary & Community Consensus Picks - newser.com
Using flow based indicators on Keros Therapeutics Inc.July 2025 Update & AI Powered Market Entry Strategies - newser.com
Keros Therapeutics Inc. stock trendline breakdownWeekly Investment Recap & AI Optimized Trading Strategy Guides - newser.com
Keros Therapeutics (NASDAQ:KROS) Trading Up 10.8%Still a Buy? - MarketBeat
Why Keros Therapeutics Inc. stock remains undervaluedLong Setup & Accurate Entry/Exit Alerts - newser.com
Published on: 2025-10-20 18:43:57 - newser.com
Reversal indicators forming on Keros Therapeutics Inc. stockPortfolio Risk Report & Weekly High Potential Stock Alerts - newser.com
What hedge fund activity signals for Keros Therapeutics Inc. stockTrade Ideas & Long-Term Investment Growth Plans - newser.com
Can trapped investors hope for a rebound in Keros Therapeutics Inc.July 2025 Catalysts & Reliable Momentum Entry Alerts - newser.com
Keros Therapeutics Inc. stock daily chart insightsMarket Performance Recap & Capital Efficient Trade Techniques - newser.com
Keros Therapeutics (KROS) Launches $194.4 Million Stock Buyback - GuruFocus
Wells Fargo & Company Initiates Coverage on Keros Therapeutics (NASDAQ:KROS) - MarketBeat
Will breakout in Keros Therapeutics Inc. lead to full recovery2025 Fundamental Recap & Reliable Price Breakout Alerts - newser.com
Keros Therapeutics (KROS) Initiates Tender Offer for Share Buyback - GuruFocus
Keros Therapeutics Launches Tender Offer for Up to $194.4 Million of Shares - MarketScreener
Keros Therapeutics (KROS) Initiates $194.4M Stock Buyback Progra - GuruFocus
Keros Therapeutics launches $194.4 million share repurchase tender offer - Investing.com
Keros (KROS) launches fixed-price cash tender offer for shares - Stock Titan
$194.4M Tender Offer — Keros Therapeutics to Repurchase at $17.75; Part of $375M Program. Expires Nov. 18, 2025 - Stock Titan
Historical volatility pattern of Keros Therapeutics Inc. visualized2025 Valuation Update & High Accuracy Trade Alerts - newser.com
Keros Therapeutics (NASDAQ:KROS) Major Shareholder Sells $84,975,125.25 in Stock - MarketBeat
Chipmakers Recap: Is Keros Therapeutics Inc. stock supported by strong fundamentalsWeekly Profit Report & Real-Time Volume Analysis - nchmf.gov.vn
What momentum indicators show for Keros Therapeutics Inc. stockQuarterly Profit Summary & Daily Entry Point Alerts - nchmf.gov.vn
Is Keros Therapeutics Inc. stock supported by strong fundamentalsWeekly Trade Review & Accurate Buy Signal Notifications - nchmf.gov.vn
Is Keros Therapeutics Inc. stock a buy on dipsWatch List & Advanced Swing Trade Entry Alerts - nchmf.gov.vn
Earnings visualization tools for Keros Therapeutics Inc.Trade Ideas & Daily Stock Momentum Reports - newser.com
Sarcopenia Market Insights Highlight Expanding Outlook Till - openPR.com
Sarcopenia Market Insights Highlight Expanding Outlook Till 2034, DelveInsight Evaluates | TNF Pharma, Lipocine, Biophytis, ImmunoForge, Rejuvenate Biomed, Keros Therapeutics, BPGbio, Oncocross - Barchart.com
Pontifax funds sell Keros Therapeutics (KROS) shares for $84.97m By Investing.com - Investing.com Australia
Pontifax funds sell Keros Therapeutics (KROS) shares for $84.97m - Investing.com India
KROS insiders file Form 4; Pontifax funds report stock sales - Stock Titan
How to recover losses in Keros Therapeutics Inc. stock2025 Price Action Summary & Verified Momentum Stock Ideas - newser.com
Is Keros Therapeutics Inc. stock poised for growthSwing Trade & Community Consensus Picks - newser.com
Keros Therapeutics, Inc. (KROS) Stock Analysis: Unpacking a 67% Potential Upside Amidst Robust Revenue Growth - DirectorsTalk Interviews
Forecasting Keros Therapeutics Inc. price range with options dataWall Street Watch & Long-Term Capital Growth Ideas - newser.com
Keros Therapeutics (NASDAQ:KROS) Major Shareholder Adar1 Capital Management, Llc Sells 5,389,264 Shares - MarketBeat
Keros Therapeutics, Inc. (NASDAQ:KROS) Looks Inexpensive But Perhaps Not Attractive Enough - 富途牛牛
Keros Therapeutics Unveils Major Capital Return Initiative Amid Leadership Reshuffle - AD HOC NEWS
Keros Therapeutics Sparks Market Interest With Nasdaq Futures - Kalkine Media
Keros Therapeutics Plans Major Buyback And Tender Offer - Finimize
Adar1 partners sells Keros Therapeutics (KROS) shares worth $95.6m By Investing.com - Investing.com Nigeria
Adar1 partners sells Keros Therapeutics (KROS) shares worth $95.6m - Investing.com
Keros Therapeutics (NASDAQ:KROS) Sees Unusually-High Trading VolumeTime to Buy? - MarketBeat
Keros Therapeutics Announces Plan for Return of $375 Million In Excess Capital - citybiz
Finanzdaten der Keros Therapeutics Inc-Aktie (KROS)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.75%
0.88%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):